Experimental Hematology
Volume 36, Issue 7 , Pages 771-772 , July 2008

Reply to Hérodin and Drouet: “Myeloprotection Following Cytotoxic Damage: The Sooner the Better”

  • Maxim Yankelevich, M.D.

      Affiliations

    • Corresponding Author InformationOffprint requests to: Maxim Yankelevich, M.D., NN Blokhin Russian Cancer Research Center, Institute for Pediatric Oncology and Hematology, 24 Kashirskoye shosse, Moscow 115478, Russian Federation.

References 

  1. Yankelevich M, Goodell MA, Kaplan J. Efficacy of delayed administration of postchemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics. Exp Hematol. 2008;36:9–16
  2. Tanikawa S, Nose M, Aoki Y, Tsuneoka K, Shikita M, Nara N. Effects of recombinant human granulocyte colony-stimulating factor on the hematologic recovery and survival of irradiated mice. Blood. 1990;76:445–449
  3. Kim SK, Demetri GD. Chemotherapy and neutropenia. Hematol Oncol Clin North Am. 1996;10:377–395
  4. Stroncek DF, Clay ME, Petzoldt ML, et al. Treatment of normal individuals with granulocyte colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996;36:601–610
  5. Tassi C, Tazzari PL, Bonifazi F, et al. Short- and long-term hematological surveillance of healthy donors of allogeneic peripheral hematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant. 2005;36:289–294

PII: S0301-472X(08)00072-6

doi: 10.1016/j.exphem.2008.02.006

Experimental Hematology
Volume 36, Issue 7 , Pages 771-772 , July 2008

Article Tools